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SUMMARY
How cells adapt metabolism to meet demands is an
active area of interest across biology. Among a broad
range of functions, the polyamine spermidine is
needed to hypusinate the translation factor eukary-
otic initiation factor 5A (eIF5A).We show here that hy-
pusinated eIF5A (eIF5AH) promotes the efficient
expression of a subset of mitochondrial proteins
involved in the TCA cycle and oxidative phosphoryla-
tion (OXPHOS). Several of these proteins have mito-
chondrial targeting sequences (MTSs) that in part
confer an increased dependency on eIF5AH. In mac-
rophages, metabolic switching between OXPHOS
and glycolysis supports divergent functional fates
stimulated by activation signals. In these cells, hypu-
sination of eIF5A appears to be dynamically regu-
lated after activation. Using in vivo and in vitro
models, we show that acute inhibition of this
pathway blunts OXPHOS-dependent alternative acti-
vation, while leaving aerobic glycolysis-dependent
classical activation intact. These results might have
implications for therapeutically controlling macro-
phage activation by targeting the polyamine-eIF5A-
hypusine axis.
INTRODUCTION
Aberrant metabolic rewiring can have pathological conse-
quences. This is evident in cells of the immune system, where
metabolic pathways and their metabolites not only provide en-
ergy and substrates for growth and survival, but also instruct dif-
ferentiation, gene expression, and effector functions important
Context and Significance
Macrophages play key physiological roles, including combating infections and cancer. The underlying metabolism of mac-
rophages is linked to their function and modulation of metabolic pathways in immune cells for therapeutic purposes is an
active area of investigation. Researchers at the Max Planck Institute in Freiburg, Germany, discovered that a fundamental
metabolic pathway (polyamine biosynthesis), which had previously been linked to essential cellular processes, such as DNA
repair, is intricately involved in cellular respiration and macrophage function by regulating mitochondrial proteins. Poly-
amine biosynthesis results in a specific chemical modification (hypusination) of the enzyme eIF5A that regulates a subset
of mitochondrial proteins involved in core respiration, thus affecting alternative macrophage activation, a cell type that
strongly engages their mitochondria. These results put the polyamine pathway and hypusination on the therapeutic map
for immune cells.
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Figure 1. The Polyamine Synthesis Pathway and Hypusinated eIF5A Modulates OXPHOS
(A) The polyamine pathway comprises the cationic metabolites putrescine, spermidine, and spermine, which are synthesized downstream of the amino acid
ornithine. Spermidine acts as a substrate for the hypusination of eIF5A, catalyzed by DHPS and DOHH. DFMO inhibits ODC, whereas DENSPM induces
polyamine catabolism. Both GC7 and CPX inhibit hypusination.
(B) Relative OCR of MEFs (NIH-3T3) incubated for 48 h with 2.5 mM DFMO ± 50 mMDENSPM assessed by Seahorse Extracellular Flux Analyzer (relative OCR =
OCR of treated cells normalized to OCR of untreated control cells).
(C) Intracellular ornithine, putrescine, spermidine, and spermine levels detected by LC-MS of MEFs treated as in (B).
(D) Relative OCR, maximum OCR, and western blot analysis of eIF5AH levels in MEFs treated with 10 mMGC7 for 24 h (relative OCR = basal OCR of treated cells
normalized to basal OCR of untreated control cells).
(legend continued on next page)
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for host immunity and tissue homeostasis (Buck et al., 2017). Un-
derstanding how immune cells control metabolic pathways,
engaging one or dampening another, may provide valuable
insight into controlling cellular functions by redirecting
metabolism.
Polyamines have roles in cellular proliferation, autophagy,
binding DNA, and modulating ion channels (Miller-Fleming
et al., 2015; Pegg, 2016). In eukaryotes, the polyamine spermi-
dine also serves as a substrate for the hypusination of a
conserved lysine residue in eukaryotic initiation factor 5A
(eIF5A) (Park et al., 1981) by the action of two enzymes, deoxyhy-
pusine synthase (DHPS) and deoxyhypusine hydroxylase
(DOHH) (Abbruzzese et al., 1986; Wolff et al., 1995). There are
two isoforms of eIF5A, eIF5A1 (we refer to this isoform as eIF5A
in this study), which is expressedubiquitously, andeIF5A2,which
is only expressed in the testes and brain (Jenkins et al., 2001).
Although originally thought to initiate translation, eIF5AH actually
promotes general translation elongation and termination (Saini
et al., 2009) (Schuller et al., 2017). It has also been linked to the
efficient translation of select mRNA subsets (Kang and Hershey,
1994), such as those containing consecutive proline codons (Gu-
tierrez et al., 2013), or other sequence-specific properties (Pele-
chano andAlepuz, 2017). Although polyamine levels are elevated
inmost cancers, and eIF5A is recognized as a critical regulator of
cell growth and tumor development (Nakanishi and Cleveland,
2016), precisely how these pathways coordinate to support cell
metabolism in healthy cells is unclear.
RESULTS
Polyamine Synthesis and Hypusinated eIF5A Modulate
OXPHOS
To investigate how polyamine biosynthesis (Figure 1A) contrib-
utes to metabolism we exposed murine embryonic fibroblasts
(MEFs) to 2-difluoromethylornithine (DFMO), an inhibitor of
ornithine decarboxylase (ODC) (Poulin et al., 1992), the enzyme
that initiates polyamine synthesis, and diethylnorspermine
(DENSPM), which induces the spermidine catabolizing enzyme
SSAT and spermidine oxidase (Stanic et al., 2009). Blocking
polyamine biosynthesis, or inducing spermidine catabolism,
reduced oxygen consumption rates (OCRs) (an indicator of
oxidative phosphorylation [OXPHOS]), while also reducing extra-
cellular acidification rates (ECARs) (an indicator of aerobic
glycolysis), although to a lesser extent (Figures 1B, S1A, and
S1B). We confirmed a decrease in putrescine, spermidine, and
spermine levels in treated cells, whereas the upstream metabo-
lite ornithine was unchanged (Figure 1C). An important cellular
function of spermidine is to provide a substrate for DHPS,
the rate-limiting enzyme during eIF5AH formation (Park et al.,
1981) (Figure 1A). Cells exposed to the DHPS inhibitor GC7
(Melis et al., 2017), or ciclopirox (CPX), a DOHH inhibitor
(Hoque et al., 2009), also dampened OXPHOS (Figures 1D and
1E). Immunoblot with an eIF5AH-specific antibody (Nishiki
et al., 2013) confirmed that eIF5AH was decreased after GC7
treatment.
Although pharmacological inhibitors often have off-target ef-
fects, which can confound results, they also can permit the acute
inhibition of a particular target. As long as results are interpreted
cautiously, this approach can be helpful when studying a
pathway as central as respiration. Genetic evidence can support
inhibitor studies, but also must be interpreted carefully, as ge-
netic models often result in a more chronic deletion, depending
on the techniques used to delete a specific gene. With these ca-
veats in mind, we examined the loss of respiration genetically by
acutely knocking down components of this pathway. We trans-
duced isopropyl b-D-1-thiogalactopyranoside (IPTG)-inducible
Eif5a-small hairpin RNA (shRNA) into MEFs (Figures 1F and
S1C) and observed a direct correlation between eIF5A expres-
sion and respiration (Figure 1G). Cells with tamoxifen-induced
deletion of Dhps (Figure 1H) displayed a similar loss of OCR (Fig-
ure 1I), while these treatments had varying effects on ECARs
(Figures S1D–S1H). Cell viability was unaffected in drug-treated
MEFs (data not shown) and in those expressing Eif5a-shRNA for
5 days (Figure S1I). Collectively, our results show that damp-
ening any one of several components of the polyamine-eIF5AH
pathway, either by acute pharmacological or genetic inhibition,
limits OXPHOS, a process conserved across cell types and spe-
cies (Figures 1J and S1J).
Hypusinated eIF5A Maintains Tricarboxylic Acid Cycle
and ETC Integrity in Macrophages
To assess the extent of this respiration defect, we exposedMEFs
to 2-deoxyglucose, which enforces OXPHOS by limiting glycol-
ysis. MEFs expressing Eif5a-shRNA, or depleted for Dhps, did
not compensate by enhancing OCRs compared with controls
(Figures S1K–S1N), revealing that, when forced, cells with insuf-
ficient levels of eIF5A or eIF5AH are unable to promotemitochon-
drial respiration in this setting. To further probe respiratory
function controlled by eIF5A, we generated mouse bone-
marrow-derived macrophages (BMM4) and then activated
them with interleukin-4 (IL-4) (M(IL-4)). IL-4-driven activation of
these cells depends on mitochondrial respiration (Vats et al.,
2006), while lipopolysaccharide (LPS)/interferon g (IFN-g)-driven
activation depends on aerobic glycolysis (Tannahill et al., 2013).
Since M(IL-4) and LPS/IFN-g-activated macrophages (M(LPS/
IFN-g)) do not proliferate to an appreciable extent in vitro (Arpa
et al., 2009; Liu et al., 2016), we could assess the role of poly-
amine biosynthesis on respiration dissociated from its regulation
(E) Relative OCR (relative OCR = basal OCR of treated cells normalized to basal OCR of untreated control cells) andmaximumOCR (OCR post-FCCP injection) in
MEFs treated with 20 mM CPX for 24 h (OCR is normalized to the baseline OCR of untreated cells).
(F and G) Immunoblot analysis of eIF5A (F) and relative OCR of MEFs (NIH-3T3) expressing isopropyl b-D-1-thiogalactopyranoside (IPTG)-inducible Eif5a-shRNA
(G). Cells were treated with 100 mM IPTG for the indicated length of time. OCR is normalized to the baseline OCR of non-IPTG-treated control cells.
(H and I) Western blot of DHPS, total eIF5A, and eIF5A-hypusine levels (H) and relative OCR in Dhpsflox/flox MEFs expressing a 4-OHT-inducible Cre (Cre-ER)
(controls are 4-OHT-treated Dhpsflox/flox Cre-ER cells) (I). OCR is normalized to the baseline OCR of control cells. Cells were treated with 10 mM 4-OHT for the
indicated length of time.
(J) S2 (D.melanogaster), Madin-Darby Canine Kidney (MDCK) (C. familiaris), andMCF-7 (H. sapiens) cells treatedwith 10 mMGC7 and 20 mMCPX for 24 h. All data
are means ± SEM (p** < 0.005, p*** < 0.0005, compared with control or untreated). (B)–(E) and (J) Representative of two experiments and (F)–(I) representative of
three experiments.
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Figure 2. Hypusinated eIF5A Maintains TCA Cycle and ETC Integrity in Macrophages
(A) TCA cycle schematic highlighting points of entry for glucose, palmitate, and glutamine.
(B) LC-MS quantification of indicated metabolites in M(IL-4) exposed to 10 mM GC7 for 24 h, relative to control cells.
(legend continued on next page)
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of proliferation (Figure S1O) (Thomas and Thomas, 2001). Similar
to the data from MEFs, ablating eIF5AH, either genetically or
pharmacologically (Figures S1P and S1Q), blocked respiration
in M(IL-4) (Figures S1R–S1T), while having varying effects on
ECARs (Figures S1U–S1W).
To probe how eIF5AH affects respiration, we analyzed
Eif5a-shRNA-expressing MEFs and GC7-treated M(IL-4) by
liquid chromatography-mass spectrometry (LC-MS) and found
decreased metabolites associated with the first half of the tricar-
boxylic acid (TCA) cycle (Figures 2A, 2B, and S2A), as well as
additional alterations in other metabolic pathways (Figures S2B
and S2C). Next, we cultured M(IL-4) with 13C-labeled glucose,
glutamine, or palmitate and traced carbon from these substrates
into metabolites. GC7-treated M(IL-4) incorporated significantly
less carbon from 13C-glucose into TCA cycle metabolites
compared with control cells (Figure 2C), indicating that DHPS
function, and thus eIF5AH, is needed for TCA cycle engagement.
Incorporation of 13C-glutamine and palmitate carbons into TCA
cycle metabolites was also decreased in GC7-treated cells (Fig-
ures 2C and S2D).
eIF5AH Ablation Dampens the Expression of Some
Mitochondrial Proteins
To ascertain why TCA cycle flux was inhibited, we performed a
proteomics analysis of GC7-treated M(IL-4). Of 153 significantly
altered proteins, 63 were mitochondrial, including TCA cycle en-
zymes and ETCproteins (Figure 2D and Table S1). The one factor
that we had uncovered thus far that unified our results was that,
on acute pharmacologic or genetic inhibition of any one of
several components of the polyamine-eIF5AH pathway, we
observed decreased OXPHOS, which was consistent with dys-
regulated mitochondrial metabolism. We investigated if this
perturbation in the mitochondrial proteome highlighted by our
proteomic analysis was the cause of defective mitochondrial
respiration in the absence of eIF5AH.
To validate our proteomics data, we assessed the expression
of several mitochondrial enzymes, for which there were high
quality commercial antibodies available, in GC7-treated BMM4
(Figure 2E), Eif5a-shRNA-expressing MEFs, or Dhpsflox/flox
MEFs expressing Cre-ER (Figure 2F) by western blot. In cells
with reduced eIF5A or eIF5AH we found decreased expression
of several TCA proteins, including succinyl-CoA synthetase
(SUCLG1) and succinate dehydrogenase (SDH), supporting the
observed break in the TCA cycle (Figures 2B, 2C, and S2D).
Other proteins such as citrate synthase and isocitrate dehydro-
genase (IDH) were less affected (Figures 2E, 2F, and S2E).
Enzymes that feed substrates into the TCA cycle, such as meth-
ylmalonyl-CoA mutase (MCM) and pyruvate dehydrogenase,
were also diminished after Eif5a or Dhps deletion, or treatment
with GC7 (Figures 2F and S2F). However, the expression of
many enzymes in glycolysis, fatty acid synthesis, and the aspar-
tate-argininosuccinate shunt remained stable (Figures S2G and
S2H), which suggested that there was not a defect in general
translation. Exposing M(IL-4) or lymphoma cells to polyamine
synthesis inhibitors or CPX also resulted in deficiencies in spe-
cific TCA cycle enzymes (Figures S2I–S2K).
Since SDH has a dual role and also participates in the ETC as
complex II, we assayed ETC complexes and found that GC7-
treated M0 and M(IL-4) and MEFs deleted for Eif5a and Dhps
(Figures 2E and 2F) had dampened expression of several ETC
complex proteins. M(LPS/IFN-g) had decreased expression of
these ETC proteins regardless of GC7 treatment (Figure 2E).
Consistent with decreased TCA cycle metabolites in GC7-
treated cells (Figure 2B), we observed a partial rescue of respira-
tion on exposure to succinate (Figure S2L). Together, these data
suggest that the polyamine-eIF5AH axis supports the expression
of a subset of mitochondrial proteins in core respiration,
providing a possible explanation as to why cells with decreased
eIF5AH have reduced TCA cycle flux and OCRs.
We next assessed how eIF5AH might specifically regulate
mitochondrial protein expression, and thereby OXHPOS.
Althoughmany mitochondrial proteins were strikingly decreased
24 h following GC7 treatment (Figure 2E), transcription of the
genes encoding these proteins was not diminished 24 h
following GC7 treatment (Figure 3A), indicating that the TCA
cycle defects conferred by reduced eIF5AH were not necessarily
a direct reflection of transcriptional changes in these genes.
Polyamines and eIF5A are also known to modulate autophagy
(Eisenberg et al., 2009; Lubas et al., 2018), an important process
controlling mitochondrial quality (Pickles et al., 2018). However,
M(IL-4) macrophages treated with the autophagy inhibitor bafilo-
mycin A1 displayed normal expression of numerous mitochon-
drial proteins (Figure S3A), suggesting to us that, at least in the
context we were investigating, autophagy was not playing a
direct role.
CertainMTSs Have an Increased Dependency on eIF5AH
To explore how eIF5A might exert control over the translation of
specificmRNAs, we performed polysome analysis of control and
Eif5a-shRNA-expressing MEFs. Polysomes are thought to be a
major site of active translation (Van Der Kelen et al., 2009). We
speculated that there might be a selective loss of gene tran-
scripts from polysomes that corresponded to the proteins iden-
tified in our proteomics data as displaying a greater dependency
on eIF5AH (Table S1). Polysome profile analysis revealed
reduced polysomes in eIF5A-depleted cells (Figure 3B), in line
with previously published data and known translation defects
on eIF5A ablation (Henderson and Hershey, 2011). Consistent
with reduced polysomes, we observed that the transcripts for
eIF5A hyperdependent Sdha and Mcm moved out of the poly-
some fraction after eIF5A deletion, but the same was true for
Idh2 and Gapdh transcripts, two proteins that did not show
(C) D-13C-Glucose and 13C-glutamine gas chromatography-mass spectrometry trace analysis of M(IL-4) treated with 10 mM GC7 for 24 h.
(D) Proteomic analysis of M(IL-4) treated with 10 mM GC7 for 24 h.
(E and F) Immunoblot assessment of selected TCA cycle enzymes, as depicted in (A), and ETC-associated proteins in (E) M0, M(LPS/IFN-g) = M(L/g), andM(IL-4)
treated with 10 mM GC7 for 22 h, and in (F) MEFs (NIH-3T3) transduced with Eif5a-shRNA for the indicated amount of days or Dhpsflox/flox Cre-ER MEFs treated
with 4-OHT for the stated length of time. All data aremeans ± SEM (p** < 0.005, p*** < 0.0005). (B andC) Representative of two experiments, (D) of one experiment
(n = 3/group), and (E and F) of three experiments. *Duplicate loading control. Due to overlapping sizes, loading controls were analyzed on separate gels. Same
amount of protein was run for analyses (E).
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Figure 3. The MTS of Several Mitochondrial Enzymes Exhibit an Increased Dependency on eIF5AH for Efficient Translation
(A) Relative mRNA expression of indicated genes in M(IL-4) treated with 10 mM GC7 for 24 h.
(B) Polysome profiles of MEFs (NIH-3T3) expressing Eif5a-shRNA for 5 days versus control MEFs. The y axis indicates absorption at 254 nm, and the x axis
represents fractions separated over a 15%–55% sucrose gradient.
(C) RT-PCR analysis of indicated mRNAs in ribosome fractions generated from control and Eif5a-shRNA-expressing MEFs (NIH-3T3).
(D) Target sequences were cloned into the N terminus of mCherry fused to a degron (to limit its half-life and circumvent differential MTSmCherry half-life between
constructs) separated by a GSGSG flexible linker to allow correct and independent folding of the introduced sequences andmCherry. These were subcloned into
the MIGR1 vector and transduced into MEFs (SUCLG1 is a subunit of succinyl-CoA synthetase).
(legend continued on next page)
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increased dependency on eIF5AH in our experiments (Figure 3C).
Although these observations were consistent with a role of eIF5A
in general translation (Pelechano and Alepuz, 2017; Schuller
et al., 2017), these data did not provide us with further insight
into a mechanism of how specific mitochondrial proteins could
have an increased dependency on eIF5A for efficient translation,
and suggested that differences might occur during translation
elongation in monosomes (Heyer and Moore, 2016).
To approach this question in a targeted fashion, we reasoned
that 40% of the proteins we found to be sensitive to eIF5A in-
hibition were mitochondrial proteins, and therefore contained a
MTSs (Table S1). MTSs contain motifs, such as stretches of re-
petitive amino acids or a high frequency of charged residues,
which can lead to ribosome stalling and slower translation
(Charneski and Hurst, 2013; Sabi and Tuller, 2015). To test
whether MTSs of specific mitochondrial proteins could increase
dependency on eIF5AH for efficient expression we cloned the
MTSs of several proteins (SUCLG1, SDHA, and MCM) identified
by our proteomic and immunoblot analyses (Table S1; Figures
2E and 2F) to be eIF5AH-hyperdependent and fused them to
the N terminus of mCherry in MIGR1. We chose these proteins
based on them having known MTS sequences that we were
able to validate. In the context of these constructs, mCherry
expression would rely on the translation of the preceding
sequence (Figures 3D and S3B). As controls, in place of the
MTSs, we positioned a SV40 nuclear localization sequence
(NLS) and a control amino acid sequence made up of the first
seven residues of GFP at the N terminus of mCherry (herein
referred to as ‘‘control’’) (Figure 3D). For comparison, we exam-
ined the MTSs of IDH2 (Figure S3B), a protein suggested by our
immunoblot analyses to have reduced dependency on eIF5AH
(Figures 2F and S2E). We imaged cells to confirm that our
MTS mCherry constructs localized to mitochondria, and SV40
NLS mCherry to the nucleus (Figures 3E and S3C). Next, we
transduced these constructs into MEFs and assessed mCherry
expression by flow cytometry in the presence of Eif5a-small
interfering RNA (siRNA), Dhps-siRNA, to acutely genetically
target this pathway, or GC7, for acute pharmacological inhibi-
tion. Importantly, internal ribosome entry site (IRES)-driven
GFP expression was equivalent in cells transduced with all con-
structs, and unaffected by genetic or pharmacological deletion
of Dhps or Eif5a (Figure 3F).
Compared with control cells, or cells exposed to a nontar-
geted siRNA, mCherry expression dependent on SUCLG1,
SDHA, or MCM MTSs was decreased compared with control
or NLS mCherry (Figures 3F, 3G, and S3D). These data suggest
that, regardless of a reduction in eIF5A or eIF5AH (Figure S3E),
the MTSs of these proteins have reduced translation, consistent
with our hypothesis that these eIF5AH-dependent mitochondrial
proteins haveMTSs that could lead to slower/less efficient trans-
lation. In contrast, IDH2 MTS mCherry was more highly ex-
pressed, in line with IDH2 protein being unaffected by the loss
of eIF5AH (Figure S3D). When we exposed transduced cells to
Eif5a-siRNA, Dhps-siRNA, or GC7 the expression of SUCLG1,
SDHA, and MCM MTS mCherry was further abrogated relative
to untreated cells or cells exposed to a nontargeted siRNA (Fig-
ures 3F, 3G, and S3F). This effect was much less apparent on
IDH2 MTSs, SV40 NLS, and control mCherry expression.
To confirm that the MTSs of select mitochondrial proteins
contain amino acid sequences that confer eIF5A hyperdepend-
ency, we swapped the C terminus half of the IDH2 MTSs for
the C terminus half of SUCLG1 MTSs and fused that novel
sequence to the N terminus of mCherry. Whereas normal IDH2
MTSs translation exhibited little sensitivity to GC7, the domain
swap of C terminus SUCLG1 MTSs resulted in significantly
decreased translation in response to GC7 (Figure S3G). Normal
SUCLG1 MTS translation exhibited high sensitivity to eIF5AH in-
hibition; however, when we fused the N terminus half of SUCLG1
MTSs to the C terminus half of IDH2 MTSs at the beginning of
mCherry, we observed no decrease in translation of this product
in response to GC7 (Figure S3G). These data suggest that se-
quences in SUCLG1 MTSs require eIF5AH for optimal transla-
tion, while the IDH2MTS sequence has a comparatively reduced
requirement for eIF5AH, explaining the loss of SUCLG1 protein,
but normal IDH2 levels during eIF5AH ablation. These observa-
tions support our conclusion that, for this set of proteins
examined, the MTS sequences lead to slower translation and
therefore show increased dependency on eIF5AH, a protein
known to facilitate efficient translation of transcripts with specific
sequence properties (Pelechano and Alepuz, 2017; Schuller
et al., 2017).
A Role for eIF5AH in Regulating Differential Macrophage
Activation
We next wanted to delineate the housekeeping function of
eIF5AH from its apparent function in specifically modulating
mitochondrial respiration. Given that immune cell activation
causes changes in the level of engagement of respiration,
we investigated whether hypusine formation could be dynam-
ically regulated in response to immune stimuli. We analyzed
eIF5A and eIF5AH expression in M(LPS/IFN-g) and M(IL-4) at
various times after activation. With the exception of 4 h after
stimulation, eIF5AH was not increased in BMM4 following
exposure to LPS/IFN-g, while eIF5AH was induced after acti-
vation with IL-4 (Figure 4A), demonstrating that eIF5AH levels
are modulated in response to these different immune stimuli.
The increased eIF5AH apparent in M(IL-4) after activation
correlated with an enrichment in the expression of hypu-
sinating enzymes in these cells compared with M(LPS/IFN-g)
(Figure S4A). We also observed an increase in the flux of argi-
nine into putrescine in M(IL-4) compared with M(LPS/IFN-g)
(Figure 4B), suggesting that dynamic regulation of substrates
(E) Representative confocal images of cloned constructs SV40 NLS-, IDH2 MTS-, and control mCherry. Scale bar, 10 mm.
(F) Representative histograms of indicated constructs in MEFs (NIH-3T3) ± 10 mM GC7 for 24 h.
(G) Indicated constructs were transfected with Eif5a siRNA plus a nontargeting AF647-labeled siRNA as a control for transfection into MEFs (NIH-3T3). Control
cells only received nontargeting siRNA. mCherry mean fluorescence intensity (MFI) was assessed 48 h after transfection by flow cytometry. Shown are repre-
sentative histograms. Histograms are gated on GFP+ AF647+ cells. Bar graphs depict percent reduction of mCherry MFI between Eif5a siRNA and nontargeting
siRNA: NS, nonsignificant; NR, no reduction in mCherry (n = 3/group). All data aremeans ± SEM (p* < 0.05, p** < 0.005, p*** < 0.0005). (A) Representative of two to
three experiments (n = 3 per group), (B and C) of one experiment, (E) of two experiments, and (F and G) of three to four experiments.
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Figure 4. A Role for eIF5AH in Differential Macrophage Activation
(A) Immunoblot analysis and densitometry of eIF5A and eIF5AH levels in BMM4 exposed to LPS plus IFN-g or IL-4 for the indicated length of time. Representative
of three individual mice.
(legend continued on next page)
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from polyamine biosynthesis could lead to alterations in
eIF5AH levels in immune cells.
Previously, OXPHOS has been implicated in M(IL-4) activation
(Huang et al., 2014; Van den Bossche et al., 2016; Vats et al.,
2006). To test this directly we activated BMM4 with IL-4 in the
presence or absence of mitochondrial inhibitors. We observed
significantly impaired expression of CD206, CD301, and Arg1
during complex I inhibition (with rotenone), complex III inhibition
(with antimycin A and myxothiazol), and complex V inhibition
(with oligomycin), supporting that mitochondrial respiration is
important for macrophage alternative activation (Figures 4C
and S4B). We next assessed markers of alternative activation
in M(IL-4) on acute eIF5AH inhibition. Reducing eIF5AH blunted
RELMa expression (Figures 4D and S4C), while GC7 and CPX
treatment, or genetic ablation of Eif5a, Dhps, or Dohh, blunted
Arg1, CD301, and CD206 to varying degrees (Figures 4D and
S4D–S4G), indicating reduced alternative activation, despite
intact IL-4 signaling through STAT6 (Figure S4H). Proteomics
data of GC7-treated M(IL-4) confirmed the decline of many pro-
teins associated with alternative activation, including CD301
(Figure 2D; Table S1). Human monocyte-derived macrophages
exposed to IL-4 also exhibited increased eIF5AH (Figure S4I)
and GC7 treatment potently reduced expression of alternative
activation markers in these cells (Figures 4E and S4J), suggest-
ing that eIF5AH is also required for human M(IL-4) activation. To
test if IL-4 could induce eIF5AH in vivo, we administered IL-4 as a
complex (IL-4c) into the peritoneal cavity of mice and assessed
eIF5A and eIF5AH expression. While total eIF5A levels remained
stable following exposure to IL-4c, eIF5AH was significantly
increased, again illustrating that hypusination is a dynamically
regulated process in macrophages (Figure 4F). Furthermore,
the in situ peritoneal accumulation of macrophages in response
to IL-4c, a hallmark of alternative activation in vivo (Jenkins et al.,
2011), was diminished in the presence of GC7 (Figure 4G). These
data support the idea that eIF5AH has a prominent role in macro-
phages that rely on OXPHOS.
To further test the function of eIF5AH in alternative macro-
phage activation and protective immunity in vivo, we infected
mice with the intestinal helminth parasite Heligmosomoides
polygyrus. Mice were pre-treated with IL-4c on days 4, 2,
and 0 before infection to drive the expansion of alternatively acti-
vated macrophages. Some mice were injected daily with GC7
between days 4 and 0. This experimental design allowed
us to more specifically target macrophages without directly
affecting the ensuing T cell response. On day 15 after infection
we found significantly increased numbers of macrophages in
the peritoneal cavity alongside a reduced number of worms in
the intestines, and eggs in the feces whenmice were pre-treated
with IL-4 (Figures 4H and S4K). This effect was lost in mice pre-
treated with GC7, indicating reduced alternative macrophage
polarization (Figures 4H and S4K). We saw no reduction of the
TH2 response after GC7 (data not shown).
Consistent with the idea that eIF5AH activity is most critical in
cells that depend on increased respiration, markers of classical
macrophage activation, such as nitric oxide synthase 2
(NOS2), major histocompatibility complex class II (MHCII), and
CD86 were unchanged in M(LPS/IFN-g), cells that rely on aero-
bic glycolysis, following genetic or pharmacological targeting
of components of the eIF5AH pathway (Figures S4L–S4N). To
substantiate these observations in vivo, we injected LPS into
the peritoneal cavity of mice to elicit classical macrophage acti-
vation. Macrophages frommice coinjected with GC7maintained
CD86, MHCII, NOS2, and serum IL-6 and IL-12 levels similar to
those in controls treated with LPS alone (Figure 4I). Together
these data suggest that classical macrophage activation re-
mained unchanged after GC7 treatment.
DISCUSSION
Many inhibitors have off-target effects; however, they remain
valuable tools. Genetic models can also come with caveats, as
they usually present a longer-term, more chronic deletion that
can confound more proximal effects that occur when a gene is
initially deleted. We have taken a broad approach in this study
using many compounds and acute genetic deletion models to
probe the polyamine-eIF5AH axis. The blend of these ap-
proaches has led us to conclude that the polyamine-eIF5AH
axis plays a role in regulating mitochondrial respiration, at least
in part, by influencing the expression of distinct subset of mito-
chondrial enzymes. Our findings are supported by a report that
genetic and GC7-driven inhibition of eIF5AH silences mitochon-
dria in kidney cells, preventing anoxic cell death and improving
kidney transplant outcome (Melis et al., 2017). Our observations
suggest that the MTS we identified as having an increased
(B) 13C-Arginine trace analysis inM0,M(LPS), M(L/g), andM(IL-4). Cells were polarized overnight in SILACmedia containing 1.1mM 13C arginine ± 2.5mMDFMO.
(C) Expression of macrophage alternative activation markers assessed by flow cytometry in BMM4 exposed to IL-4 ± 500 nM rotenone (complex I inhibitor) or
5 mM antimycin A (complex III inhibitor) or 200 nM myxothiazol (complex III inhibitor) or 5 mM oligomycin (complex V inhibitor) for 20 h (n = 7).
(D) CD301 and RELMa expression assayed by flow cytometry in M(IL-4) treated with 10 mM GC7 or 20 mM CPX for 24 h.
(E) Expression of human macrophage alternative activation markers assessed by flow cytometry in human monocyte-derived macrophages exposed to IL-4 ±
10 mM GC7 for 20 h (n = 3 individual donors).
(F) C57BL/6 mice were administered IL-4:aIL-4 complex at 5:25 mg by intraperitoneal (i.p.) injection. 24 h later eIF5A and eIF5AH levels were assessed by flow
cytometry in peritoneal macrophages (Ly6G Ly6C Siglec-F F4/80hi CD11b+) (n = 5 per group).
(G) Absolute number of peritoneal macrophages elicited from mice treated with IL-4:aIL-4 complex at 5:25 mg on days 2 and 4 ± 10 mg/kg GC7 on days 0–3
(n = 4–5 per group).
(H) C57BL/6 mice were treated with IL-4:aIL-4 complex by i.p. injection at 5:25 mg on days 4, 2, and day 0 ± 10 mg/kg GC7 on days 4 to 0. On day 0, mice
were orally infected with H. polygyrus by gavage and absolute counts of peritoneal macrophages and intestinal worm burden were assessed on day 15 post-
infection (B = naive control) (n = 6 per group).
(I) Mice were treated with 8 mg/kg LPS ± 10 mg/kg GC7 by i.p. injection, 12-h later serum IL-12 and IL-6 levels were quantified, as were markers of classical
macrophage activation in peritoneal macrophages (Ly6G Ly6C Siglec-F F4/80hi CD11b+) measured by flow cytometry (n = 5 per group). All data are means ±
SEM (p* < 0.05, p** < 0.005, compared with M(IL-4) condition, or IL-4c). (A) Representative of three individual mice and two experiments, (B, C, G, and I) of two
experiments, (D) of three experiments, and (E, H) of one experiment.
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dependency on eIF5AH were expressed less efficiently, denoted
by their decreased mCherry expression. These results sug-
gested to us that the selectivity of enhanced eIF5AH depen-
dency, at least in one aspect, might be at the level of translational
efficiency. Precisely how eIF5AH mediates this effect is not
known. Interestingly, eIF5A has been shown to copurify with
mitochondrial proteins (Pereira et al., 2016), but how the poten-
tial mitochondrial targeting of eIF5A might influence our results
here is not clear.
Both polyamine synthesis and eIF5A expression are
augmented in cancer cells (Casero and Marton, 2007; Mathews
and Hershey, 2015). Although these changes were largely
thought to be important for driving proliferation, our data suggest
tha these alterations might also affect mitochondrial activity in
cancer cells. Previous studies have also demonstrated the
engagement of polyamine biosynthesis and eIF5A in immune
cells (Bevec et al., 1994; Hukelmann et al., 2016; Wang et al.,
2011), and we believe our results here highlight an important
function of this pathway in controlling OXPHOS. In line with pre-
vious reports (Huang et al., 2014; Van den Bossche et al., 2016;
Vats et al., 2006), we confirm an important role for OXPHOS in
macrophage alternative activation. Recent analysis of alternative
activation at the mRNA level during ETC complex inhibition sug-
gested that OXPHOS was dispensable for M(IL-4) (Divakaruni
et al., 2018), these observations might imply that OXPHOS reg-
ulates M(IL-4) activation in a post-transcriptional manner. At
the outset of our study we viewed this pathway to control mito-
chondrial metabolism, one that may remain on in the basal state,
but could also be dynamically regulated to ramp up or down, de-
pending on activation state and needs of the cell. However, our
data showing that M0macrophages havemuch less eIF5AH than
M(IL-4) macrophages at 4, 12, or 24 h after activation suggest
that this is not the case, as both cell types seem to have similar
expression of mitochondrial enzymes we identify as having an
enhanced dependency on eIF5AH. Nevertheless, M(IL-4) have
higher respiration rates thanM0, perhaps suggesting that eIF5AH
has additional effects on other proteins that promote TCA flux
and OXPHOS. Indeed, our proteomics study revealed 90 pro-
teins that were hyperdependent on eIF5AH, but were not mito-
chondrial proteins. More work is needed to determine the full
scope of how hypusine and eIF5A influences mitochondrial ac-
tivity in these cells.
Our data suggested that, at least for the few MTS we studied,
sequence-specific properties conferred increased dependency
on eIF5AH. Given that the SV40 NLS, which is rich in positively
charged residues, is not subject to eIF5AH regulation in this
study, it is unlikely that the presence of positively charged resi-
dues alone confers specificity. Recent evidence notes that the
location of these residues may play a role in regulation by
eIF5AH, suggesting that MTS secondary structure or other ele-
ments may influence ribosome stalling and hence reliance on
eIF5AH (Pelechano and Alepuz, 2017; Schuller et al., 2017).
The precise nature of the sequence-specific properties, or any
potential structural differences in MTS, or how additional factors
modulate the ultimate effect eIF5AH has on their translation, has
yet to be determined.
We remain interested in the upstream signals that influence
the polyamine-eIF5AH pathway in immune cells. We specu-
late that the enrichment of eIF5AH in M(IL-4) is driven by an
upturn in substrate abundance. Increased ornithine in M(IL-4)
due to upregulated arginase expression results in enhanced
substrate for ODC to generate putrescine, and ultimately
spermidine, which can be used to synthesize hypusine. A sce-
nario such as this may mean that, even if expression of poly-
amine-hypusine enzymes is not altered, hypusine synthesis
can be augmented because of increased ornithine, putrescine,
and spermidine availability. Overall, our data suggest that
arginase expression during macrophage alternative activation
serves to promote hypusination to support mitochondrial
metabolism.
Arginase is expressed in several immune cell types (Bando
et al., 2013; Monticelli et al., 2016; Pesce et al., 2009), and its
expression in macrophages leads to the breakdown of arginine,
which acts to deplete arginine from the extracellular environ-
ment and thereby inhibit the activation of T cells that depend
on this amino acid substrate (Rodrı´guez et al., 2004). Since it
is known that polyamines are important for cell proliferation, it
is possible that cells that deplete arginine, something that
cancer cells also do to support their own proliferation, block
polyamine biosynthesis in T cells, thereby inhibiting their
proliferation. More work will need to be done to determine
how upstream substrates such as ornithine influence eIF5AH
in immune cells and whether this ultimately influences their
function.
Limitations of Study
While our study shows that the polyamine-eIF5A-hypusine axis
influences the TCA cycle and mitochondrial respiration, and
thus controls macrophage activation, a full understanding of
how eIF5AH affects the expression of specific proteins, and in
particular certain MTS, remains to be determined. Our experi-
ments do not delineate whether eIF5AH directly effects transla-
tion of certain transcripts, or whether it acts through an indirect
mechanism that ultimately affects the expression of certain
proteins.
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STAR+METHODS
KEY RESOURCES TABLE
REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Anti-Hypusine Millipore, Polyclonal, ABS1064
Anti-eif5a BD Biosciences 26/eIF-5a
Anti-GAPDH Cell Signaling, D16H11
Anti- alpha tubulin Sigma DM1A
Anti-rabbit DHPS Abcam Polyclonal, ab190266
Anti- hexokinase II Cell signaling C64G5
Anti- IDH2 Cell signaling D7H6Q
Anti- DLD (lipoamide dehydrogenase) Abcam, EPR6635
Anti- SUCLG1 (succinyl CoA Synthetase) Cell Signaling Polyclonal, 5557
Anti- SDHA (succinate dehydrogenase A) Cell Signaling D6J9M
Anti- SDHB (Succinate dehydrogenase B) Abcam 21A11AE7
Anti- methylmalonyl coA mutase Abcam EPR7738
Anti- rodent oxphos cocktail Abcam Monoclonal mix, ab110413
Anti- citrate synthase Cell signaling D7V8B
Anti- IDH2 Cell Signaling D7H6Q
Anti- MDH2 (malate dehydrogenase 2) Cell signaling D8Q5S
Anti- DOHH Abcam Polyclonal, ab122946
Anti-PDH (pyruvate dehydrogenase) Cell signaling C54G1
Anti-GLDH (glutamate dehydrogenase Cell signaling D9F7P
Anti-ABAT (4-aminobutyrate
aminotransferase)
Abcam EPR4433
Anti-ASL (argininosuccinate lyase) Abcam EPR19396
Anti-ACL (Acetyl CoA Carboxylase) Cell signaling C83B10
Anti-FAS (fatty acid synthase) Cell signaling C20G5
Anti-G6PDH (glucose-6-phosphate
1-dehydrogenase)
Cell Signaling Polyclonal, 8866
Anti-hexokinase I Cell signaling C35C4
Anti-aconitase Abcam EPR7225
Anti-IDH1 Cell signalling D2H1
Ant-LC3 Sigma Polyclonal, L7543
Anti-ODC Abcam EPR5724
Anti-p-STAT6 Cell Signaling Polyclonal, 9361
Anti-COX2 Cell Signaling D5H5
Anti-NOS2 Santa Cruz C-11
Anti-CD206 Biolegend C068C2
Anti-CD301 Biorad/Biolegend ER-MP23 and LOM-14
Anti-arginase I eBioscience AlexF5
Anti-RELM alpha Peprotech polyclonal
Anti-F4/80 Biolegend BM8
Anti-CD11b Biolegend/BD M1/70
Anti-cd86 Biolegend GL-1
(Continued on next page)
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REAGENT or RESOURCE SOURCE IDENTIFIER
Anti-I-A/I-E (MHC Class II) Biolegend/eBioscience M5/114.15.2
Anti-human CD16 Biolegend Clone: 3G8
Anti-human CD71 Biolegend CY1G4
Anti-human CD206 eBioscience/Biolegend 19.2(eBioscience)
15-2 (Biolegend)
Anti-human CD209 BD/Biolegend DCN46(BD)
9E9A8 (biolegend)
Biological Samples
Blood from healthy human donors University of Freiburg CCI Biometric Bank
(IRB approval No. 282/11
Chemicals, Peptides, and Recombinant Proteins
N1,N11-Diethylnorspermine tetrahydrochloride Tocris 6618
DFMO Enzo Life
Sciences
ALX-270-283-M050
GC7 Millipore 259545
Ciclopirox Sigma SML2011
IPTG Sigma I6758
4-OHT Sigma T5648
Rotenone Sigma R8875
Antimycin A Sigma A8674
Myxothiazol Sigma T5580
Oligomycin Sigma O4876
2-Deoxyglucose Alfa Aesar L07338
FCCP Sigma C2920
Bafilomycin A1 Alfa Aesar J61835
Succinate Sigma S9637
Near IR Live-Dead fixable Thermo Catalogue No:
L10119
Live/Dead Fixable Violet Thermo L34955
C13 Glucose Cambridge Isoptope laboratories CLM-1396
C13 Glutamine Cambridge Isoptope laboratories DML-1826
C13 Palmitate Cambridge Isoptope laboratories CLM-409
Mouse Recombinant IFNgamma Peprotech 315-05
Mouse recombinant IL-4 Peprotech 214–14
Mouse recombinant M-CSF Peprotech 315-02
Human recombinant M-CSF R&D Systems 216-MC-500
Human recombinant IL-4 R&D Systems 204-IL-050
RMPI Thermo 21875158
DMEM Thermo 31885049
FCS Thermo 10099141
Glutamine Thermo 25030-024
LPS Sigma L4391
Critical Commercial Assays
IL-6 Biolegend 431303
IL-12 ELISA Biolegend 431602
(Continued on next page)
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REAGENT or RESOURCE SOURCE IDENTIFIER
Deposited Data
Proteomics Data ProteomeXchange Consortium via
PRIDE repository
PXD013443
Experimental Models: Cell Lines
NIH3T3 ATCC CRL-1658
EG7-OVA ATCC CRL-2113
Eif5a-shRNA-expressing NIH3T3 MEFs Gift from Dr Stefan Balabanov NA
Dhpsflox/flox ERT2-Cre MEFs P€allmann et al., 2015 NA
Experimental Models: Organisms and Strains
C57BL/6J mice Jackson Labs. 000664
YARG Jackson Labs 015857
Oligonucleotides
Taqman primers: Citrate
synthase (Cs)
Applied Biosystems 4331182/Mm00466043_m1
Taqman primers: Dld Applied Biosystems 4331182 /Mm00432831_m1
Taqman primers: Suclg1 Applied Biosystems 4448892/Mm00451244_m1
Taqman primers: Sdha Applied Biosystems 4331182/ Mm01352366_m1
Taqman primers: Mdh2 Applied Biosystems 4331182/ Mm00725890_s1
Taqman primers Mut Applied Biosystems 4331182 /Mm00485312_m1
Taqman primers: Idh2 Applied Biosystems 4331182 /Mm00612429_m1
Taqman primers: gapdh Applied Biosystems 4331182 /Mm99999915_g1
Recombinant DNA
MSCV-LTRmiR30-PIG
(LMP) For hp constructs
Addgene plasmid #24071
MSCV-I-GFP (MIGR1) For MTS constructs Addgene plasmid #27490
LMP-control hp Open Biosystems Addgene plasmid #24071
LMP-EIF5a hp
Black: 5’ miR30 context
Blue: EIF5a sense sequence
Green: Loop
Red: EIF5a antisense sequence
Black: 3’ miR30 context
Sigma TGCTGTTGACAGTGAGCGCCCATGAA
GATATCTGCCCGTCAATAGTGAAGCC
ACAGATGTATTGACGGGCAGATATCT
TCATAGTTGCCTACTGCCTCGGA
LMP-Dhps hp
Black: 5’ miR30 context
Blue: Dhps sense sequence
Green: Loop
Red: Dhps antisense sequence
Black: 3’ miR30 context
Sigma TGCTGTTGACAGTGAGCGCCCACATC
CCTGTGCTGAGTCCATAGTGAAGCCA
CAGATGTATGGACTCAGCACAGGGAT
GGTTGCCTACTGCCTCGGA
LMP-Dohh hp
Black: 5’ miR30 context
Blue: Dohh sense sequence
Green: Loop
Red: Dohh antisense sequence
Black: 3’ miR30 context
Sigma TGCTGTTGACAGTGAGCGCCCGTGCTG
CATGAATAAAATATAGTGAAGCCACAG
ATGTATATTTTATTCATGCAGCACGGTT
GCCTACTGCCTCGGA
(Continued on next page)
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mcs-GSGSG-mCherryDEG
Black: multiple cloning site (XhoI-BamHI)
Yellow: BamHI site GSGSG linker
Red: mCherry
Green: ODC degron
Black: EcoRI cloning site
IDT CTCGAGCCAACTGGATCCGGCTCCGG
CTCCGGAGTGAGCAAGGGCGAGGAGG
ATAACATGGCCATCATCAAGGAGTTCA
TGCGCTTCAAGGTGCACATGGAGGGCT
CCGTGAACGGCCACGAGTTCGAGATCG
AGGGCGAGGGCGAGGGCCGCCCCTAC
GAGGGCACCCAGACCGCCAAGCTGAA
GGTGACCAAGGGTGGCCCCCTGCCCT
TCGCCTGGGACATCCTGTCCCCTCAG
TTCATGTACGGCTCCAAGGCCTACGT
GAAGCACCCCGCCGACATCCCCGACT
ACTTGAAGCTGTCCTTCCCCGAGGGC
TTCAAGTGGGAGCGCGTGATGAACTT
CGAGGACGGCGGCGTGGTGACCGTG
ACCCAGGACTCCTCCCTGCAGGACGG
CGAGTTCATCTACAAGGTGAAGCTGCG
CGGCACCAACTTCCCCTCCGACGGCCC
CGTAATGCAGAAGAAGACGATGGGCTG
GGAGGCCTCCTCCGAGCGGATGTACCC
CGAGGACGGCGCCCTGAAGGGCGAGAT
CAAGCAGAGGCTGAAGCTGAAGGACGG
CGGCCACTACGACGCTGAGGTCAAGAC
CACCTACAAGGCCAAGAAGCCCGTGCA
GCTGCCCGGCGCCTACAACGTCAACATC
AAGTTGGACATCACCTCCCACAACGAGG
ACTACACCATCGTGGAACAGTACGAACG
CGCCGAGGGCCGCCACTCCACCGGCGG
CATGGACGAGCTGTACAAGCATGGCTT
CCCGCCGGAGGTGGAGGAGCAGGATG
ATGGCACGCTGCCCATGTCTTGTGCCCA
GGAGAGCGGGATGGACCGTCACTAAGAATTC
SV40 NLS
Red: XhoI site
Blue: SV40 NLS (MPKKKRKV)
Yellow: BamHI site
IDT CTCGAGATGCCTAAAAAGAAGAGGAA
GGTAGGATCCG
SUCLG1 MTS
Red: XhoI site
Blue: SUCLG1 MTS
(MTATVVAAAATATMVSSSSGL
AAARLLSRTFLLQQNGIRHG)
Yellow: BamHI site
IDT CTCGAGATGACCGCAACAGTAGTTGCTGCG
GCTGCCACTGCAACCATGGTCTCCAGCAGC
AGCGGCCTCGCCGCCGCCCGCCTGTTGTCG
CGCACCTTCCTCCTGCAACAGAATGGGATA
CGACACGGGGGATCC
SDHA MTS
Red: XhoI site
Blue: SDHA MTS
(MAGVGAVSRLLRGRRLALTGAWPGTLQK
QTCGFHFSVGENKKASAKVSDAISTQYPVVD)
Yellow: BamHI site
IDT CTCGAGATGGCCGGGGTTGGCGCAGTTTC
GAGGCTTCTTCGCGGGCGGCGCTTGGCG
TTAACTGGGGCGTGGCCAGGAACACTCCA
AAAACAGACCTGCGGCTTTCACTTCTCTG
TTGGTGAGAACAAGAAGGCATCAGCTAAA
GTTTCAGATGCAATTTCTACTCAATACCCA
GTGGTGGATGGATCC
IDH2 MTS
Red: XhoI site
Blue: IDH2 MTS (MAGYLRAVSSLCRASG
SARTWAPAALTVPSWPEQPRRHY)
Yellow: BamHI site
IDT CTCGAGATGGCCGGCTACCTGCGGGCTGT
GAGCTCGCTCTGCAGAGCCTCGGGCTCAG
CGCGGACCTGGGCACCGGCAGCACTGACT
GTCCCCAGCTGGCCGGAGCAGCCGCGGC
GCCACTATGGATCC
MCM MTS
Red: XhoI site
Blue: MCM MTS (MLRAKNQLFLLSPHYLK
QLNIPSASRWKRLL)
Yellow: BamHI site
IDT CTCGAGATGTTGAGAGCTAAGAATCAACTT
TTTTTGCTATCGCCCCATTACCTGAAGCAG
CTAAACATTCCATCAGCTTCCAGATGGAAA
CGCCTTCTAGGATCCG
(Continued on next page)
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CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Erika
Pearce (pearce@ie-freiburg.mpg.de).
EXPERIMENTAL MODEL DETAILS
Mice and Immunizations
C57BL/6 (Jax, 000664) and Arg1-YFP C57BL/6 (Jax, 015857) were purchased from Jackson Laboratories. All mice were bred and
maintained under specific pathogen free conditions under protocols approved by the Animal Welfare Committee of the Max Planck
Institute of Immunobiology and Epigenetics, Freiburg, Germany. Mice used in all in vitro and in vivo experiments were 6–10 weeks of
age and were age/sex matched. For infection with H. polygyrus bakeri, mice were infected orally by gavage with 200 infective L3
stage larvae. At day 15 post infection, mice were sacrificed and parasite burdens were measured. To count worms, intestines
were removed, opened longitudinally, and placed on to muslin cloth draped on top of a 50 ml tube filled with complete RPMI for
4 h at 37C. Parasites migrated through the cloth into the tube and were recovered for counting on a dissecting microscope. Parasite
eggs were enumerated by soaking feces collected from individual mice in water, then diluting the fecal slurry with saturated sodium
chloride and counting under a microscope using a McMaster counting chamber. Long acting IL-4 complex (IL-4c) consisted of a 2:1
molar ratio of recombinant mouse IL-4 (Peprotech, London) and anti-IL-4 mAb (clone 11B11; BioXcell, NH) and was administered by
i.p. injection at the times indicated in the figure legend. Each mouse received 5 mg of IL-4 and 25 mg of 11B11, ± 10 mg/kg GC7
(Millipore). PBS was used as a vehicle control. For in vivo studies with LPS we administered 8mg/kg LPS (Sigma) by i.p.
injection ± 10 mg/kg GC7. IL-12 and IL-6 quantification was assessed by ELISA (eBioscience) as per the manufacturer’s instructions
on serum 3 hours after LPS injection.
Cell Culture
Bone marrow cells were differentiated for 7 days into bone marrow macrophages (BMM4) by culturing in complete medium (RPMI
1640 media supplemented with 10% FCS, 2mM L-glutamine, 100 U/mL penicillin/streptomycin) with 20 ng/mL macrophage colony-
stimulating factor (M-CSF; PeproTech). M(IL-4) were generatedwith 20 ng/mL IL-4 overnight fromday 7 of culture; M(LPS/IFNg) were
generated with 20 ng/mL LPS (Sigma) and 50 ng/mL IFN-g (R&D Systems) overnight from day 7 of culture. All drug treatments on
BMM4 began from day 7 of culture. N1-guanyl-1 7-diaminoheptane (GC7; Enzo Life Sciences) and ciclopirox (Sigma) were typically
used at 10 mMand 20 mM, respectively, unless otherwise stated. Difluoromethyl ornithine (DFMO) and diethylnorspermine (DENSPM;
Tocris) were used at 2.5mMand 50 mM, respectively. Dimethylsuccinate (Sigma) was used at 5mM. DHPSFlox/Flox Cre-ERMEFs,were
cultured in complete DMEM (DMEM supplemented with 10% FCS, 2mM L-glutamine, 100 U/mL penicillin/streptomycin) and gener-
ated as previously described (P€allmann et al., 2015). Cre-ER expression was induced with 1 mM4-OHT (Sigma) for the indicated time
period. NIH3T3MEFs (purchased from ATCC) stably transduced with Eif5a-shRNAwere grown in complete DMEM and Eif5a-shRNA
expression was induced with 100 mM isopropyl-b-D-1 thiogalactopyranoside (IPTG, Sigma) for the indicated period of time.
Continued
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N’IDH2:SUCLG1-C’ MTS
Red: XhoI site
Blue: IDH2:SUCLG1 fusion MTS
(MAGYLRAVSSLCRASGSARTWSSG
LAAARLLSRTFLLQQNGIRHG)
Yellow: BamHI site
IDT CTCGAGATGGCTGGGTACCTCCGCGCAGT
CTCAAGTCTCTGCCGGGCAAGCGGCAGCG
CCCGCACATGGTCTTCCGGTTTGGCTGCT
GCTAGACTGCTTAGTCGCACTTTTCTCCTT
CAGCAGAACGGTATTAGACACGGGGGATCCG
N’SUCLG1:IDH2-C’ MTS
Red: XhoI site
Blue: SUCLG1:IDH2 fusion MTS
(MTATVVAAAATATMVSSSSGAPAAL
TVPSWPEQPRRHY)
Yellow: BamHI site
IDT CTCGAGATGACTGCAACCGTAGTAGCCGC
AGCCGCCACAGCCACTATGGTATCCTCATC
ATCAGGCGCCCCTGCAGCCCTGACAGTAC
CATCATGGCCAGAACAGCCAAGGCGACATT
ATGGATCC
Software and Algorithms
maxLFQ algorithm Cox et al., 2014 NA
MaxQuant Cox and Mann, 2008;
Cox et al., 2011
NA
Perseus platform Tyanova et al., 2016 NA
FlowJo TreeStar NA
Prism GraphPad NA
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Madin-Darby Kidney Canine (MDCK) cells were grown in complete DMEM, aswas the human breast adenocarcinoma lineMCF-7 but
with 0.01mg/ml recombinant human insulin. D. melanogaster Schneider 2 (S2) cells were cultured without CO2 at 28
C in complete
Schneider’s Drosophila medium (Gibco; supplemented with 10% FCS, 50 U/mL penicillin/streptomycin, 25% conditioned complete
Schneider’s medium). To generate human macrophages, we negatively selected monocytes from blood using the manufacturers in-
structions (Stem Cell). All subjects gave written informed consent in accordance with the Declaration of Helsinki and the study was
performed according to the CCI Biometric Bank (IRB approval No. 282/11). Monocytes were differentiated into macrophages with
100 ng/mL human M-CSF (R&D Systems) for 6 days in complete medium (RPMI 1640 media supplemented with 10% FCS, 2mM
L-glutamine, 100 U/mL penicillin/streptomycin). On day 6, macrophages were polarised with 20 ng/mL human IL-4 (R&D Systems)
and analysed the next day.
METHOD DETAILS
Metabolic Profiling
Extracellular acidification rate (ECAR) and oxygen consumption rate (OCR) weremeasured using the Seahorse XFeBioanalyser (Sea-
horse Bioscience). 8x104 BMM4were added to sea horse 96 well plates on day 7 of culture and analysed in XF media (non-buffered
RPMI 1640 containing 25 mM glucose, 2 mM L-glutamine, and 1 mM sodium pyruvate) the following day after cytokine and drug
treatment. Prior to analysis, cells were incubated for a minimum of 45 minutes at 37C in the absence of CO2. OCR and ECAR
were measured under basal conditions, or after the addition of the following drugs: 1 mMoligomycin, 1.5 mM fluoro-carbonyl cyanide
phenylhydrazone (FCCP), 100 nM rotenone, and 1 mMantimycin A (all Sigma). Measurements were taken using a 96well Extracellular
Flux Analyser (Seahorse Bioscience).
Metabolite Tracing
BMM4 on day 7 of culture were washed and cultured in complete RPMI 1640 (minus glucose or glutamine), supplemented with either
11mM 13C-glucose or 4mM 13C-glutamine, for 24 hours. 13C-palmitate (20 mM) was added to complete RMPI 1640 overnight.
13C-Argining tracing was performed by culturing cells in SILAC media supplemented with 0.2 mM L-lysine and 1.1 mM 13C-Arginine
for 24 hours. MEFs were washed and cultured in complete DMEM (with 10% dialysed serum, minus glucose or glutamine), supple-
mented with 25 mM 13C-glucose or 4 mM 13C-glutamine, for 24 hours. For harvest, cells were rinsed with cold 0.9% NaCl and
metabolites extracted using 1.2 mL of 80% MeOH kept on dry ice. 10 nM norvaline (internal standard) was added. For putrescine
detection, metabolites were extracted in 80% MeOH containing 3% formic acid. Following mixing and centrifugation, the superna-
tant was collected and dried via centrifugal evaporation. Driedmetabolite extracts were resuspended in pyridine and derivatized with
methoxyamine (sc-263468 Santa Cruz Bio) for 60 minutes at 37C and subsequently with N-(tert-butyldimethylsilyl)-N-methyl-
trifluoroacetamid, with 1% tert-butyldimethylchlorosilane (375934 Sigma-Aldrich) for 30 minutes at 80C. Isotopomer distributions
were measured using a DB5-MS GC column in a 7890 GC system (Agilent Technologies) combined with a 5977 MS system (Agilent
Technologies). Correction for natural isotope abundance and calculation of fractional contribution was performed as described
elsewhere(Buescher et al., 2015).
Metabolite Quantification
Metabolites were quantified by LC-MS using HILIC Chromatography on an Acquity UPLC BEH Amide column 1.7 mm, 2.1x100 mm
(polyamines) or a Luna NH2 column (all other metabolites) on a 1290 Infinity II UHPLC system (Agilent Technologies) combined with
targeted detection in a 6495 MS system (Agilent Technologies). Peak areas were normalized to 13C labelled internal standard
(ISOtopic Solutions).
Western Blot
For western blot analysis, cells were washed with ice cold PBS and lysed in 1 x Cell Signaling lysis buffer (20 mM Tris-HCl, [pH 7.5],
150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM b- glycerophosphate, 1 mM
Na3VO4, 1 mg/mL leupeptin (Cell Signaling Technologies), supplemented with 1 mMPMSF. Samples were frozen and thawed 3 times
followed by centrifugation at 20,000 x g for 10 min at 4C. Cleared protein lysate was denatured with LDS loading buffer for 10 min at
70C, and loaded on precast 4% to 12% bis-tris protein gels (Life Technologies). Proteins were transferred onto nitrocellulose mem-
branes using the iBLOT 2 system (Life Technologies) following the manufacturer’s protocols. Membranes were blocked with 5%w/v
milk and 0.1% Tween-20 in TBS and incubated with the appropriate antibodies in 5%w/v BSA in TBSwith 0.1% Tween-20 overnight
at 4C. All primary antibody incubations were followed by incubation with secondary HRP- conjugated antibody (Pierce) in 5% milk
and 0.1% Tween-20 in TBS and visualized using SuperSignal West Pico or femto Chemiluminescent Substrate (Pierce) on Biomax
MR film (Kodak). Optical density of the signals on film was quantified using grayscale measurements in ImageJ software (NIH) and
converted to fold change. All antibodies were from Cell Signaling Technologies except for anti-ABAT, Anti-ACC, anti-Aconitase 1,
anti-ASL, anti-DLD, anti-DOHH, anti-DHPS, anti-MCM, anti-ODC (Abcam), anti-eIF5A (BD Bioscience), anti-hypusine (Merck-
Millipore). Electron transport chain complexes were probed with the Total OXPHOS Rodent WB Antibody Cocktail (Abcam). For
T cells, we lysed cells at 40,000/mL and loaded protein from 300,000 cells per lane. For macrophages we lysed a concentration of
25,000 cell/mL and loaded protein from 175,000 cells/lane. Due to the high total eIF5A protein found in most cells, we used different
parameters when blotting for this protein and its hypusinated form. To obtain a luminescent signal that produced bands in the linear
range of the film with reasonable exposure times (5-30 seconds), we loaded 10-fold less protein for both T cells and macrophages,
which equated to approximately 30,000 and 17,500 cells per lane, respectively.
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Retroviral Transduction
In BMM4, bonemarrow cells exposed toM-CSFwere transducedwith luciferase (empty vector) or Eif5a-,Dhps-, orDohh-expressing
retrovirus by centrifugation for 90 minutes in media containing hexadimethrine bromide on day 2 of culture. Transduced cells were
subsequently drug or cytokine-treated on day 7 of culture and assayed on day 8, sometimes following sorting on day 6. GFP was
used as a marker for transduction in these cells.
Targeted mCherry
A G-block construct (IDT) containing mCherry fused to the degron from ODC (Kelly et al., 2007) (HGFPPEVEEQDDGTLPMSCA
QESGMDRH*) (mCherrydeg) was constructed to reduce half-life of themCherry fusion protein. Between the cloning sites andmCherry
a Gly-Ser-Gly-Ser-Gly flexible linker was included, to allow correct and independent folding of the introduced sequences and
mCherry. The mCherrydeg was cloned into MSCV-I-GFP using XhoI and EcoRI. MTS, NLS, or control sequences were ordered as
G-blocks (IDT) or as phosphorylated oligos containg XhoI and BamHI compatible overhangs and cloned into MSCV-mCherrydeg-
I-GFP using XhoI and BamHI. The targeted sequences fused to mCherry are denoted in Figure 3 and extended data Figure 3.
Lentiviral Transductions
The IPTG-inducible MISSION shRNA lentiviral vector pLKO-puro-IPTG-3xLacO was purchased either with a shRNA against the
30-UTR of the murine eIF5A mRNA sequence (custom-made from #SHCLND-NM181582-TRCN0000125229; Sigma) or a corre-
sponding non-target shRNA control (#SHC332-1EA; Sigma). Stable transduction of the lentiviral was performed as previously
described(Preukschas et al., 2012) using HEK293T cells, the packaging plasmids: pMDLg/pRRE (Gag/Pol), pRSV-Rev (Rev) and
phCMV-VSV-G (envelope) as well as the ProFection Mammalian Transfection System Calcium Phosphate Kit (Promega). Positive
cells were selected using puromycin.
siRNA Knockdown of Eif5a and Dhps in MEFS
18 hours before transfection 750000 MEFS were plated in individual wells of a six well plate and left to attach overnight. Transfection
mixes were prepared in serum free (Opti-MEM)media according to themanufacturer’s recommendations. In short, 150 mLOpti-MEM
per well wasmixed with 3 mL DharmaFECT-3 reagent (GE Healthcare) and incubated for 5minutes at RT. In a separate tube 150 mL of
Opti-MEM was supplemented with 1 mM non targeting AF647 labeled siRNA oligo (GE Healthcare) with or without 5 mM Smartpool
siRNA against Eif5a or Dhps (GE Healthcare), which consists of 4 targeting oligos each. Tubes containing reagent and siRNA mixes
were mixed and incubated for 20 minutes at RT, supplemented with 1200 ml of serum free DMEM supplemented with 10% FBS
(Hyclone). Medium on cells was replaced with transfection mixture and incubated for 48 hours before analysis.
Proteomics
Sample Preparation
After cell collection, protein sample preparation was carried out as described in Kulak et al. (Kulak et al., 2014) with minor modifica-
tions. In brief, macrophages were lysed in urea buffer (8 M urea, 10 mM TCEP, 40 mM CAA, and 100 mM Tris pH8.5) and protein
concentration estimation was carried out using BradfordRed reagent (Expedeon). 50 mg total protein was digested with endoprotei-
nase lys C at a ratio of 1:50 (enzyme to protein) for 3 hours at room temperature followed by dilution of the lysate to an urea concen-
tration below 2 M and digestion with trypsin at a ratio of 1:50 (enzyme to protein) for 13 hours at 37C. Tryptic peptides were trans-
ferred to commercial centrifugal iST devices (PreOmics) and fractionated into 3 different fractions followed by clean-up/desalting and
eluted as described in (Kulak et al., 2014).
Mass Spectrometric Acquisition
General nanoLC-MS setup was similar as previously described (Engelke et al., 2014) with modifications described in the following.
QExactivemass spectrometer (Thermo Fisher Scientific, Germany) and Easy nanoLC-1000were used for all experiments. Chromato-
graphic separation of peptides was carried out on in-house packed fused-silica emitter nanoLC columns (75 mm 3 20 cm)
(Silica PicoTip; New Objective, U.S.A.) packed with 1.9 mm reverse-phase ReproSil-Pur C18-AQ beads (Dr. Maisch, Germany).
Peptides were separated by a 3h linear gradient of 5-80% buffer B (80% acetonitrile, 0.1% formic acid) at constant flow rate of
300 nL/min. For MS data acquisition the ‘‘fast’’ method from Kelstrup et al.(Kelstrup et al., 2012) was adopted.
Mass Spectrometry Data Analysis
MS raw files were analyzed by MaxQuant software and peak lists were searched against the mouse Uniprot FASTA database
(concatenated with a database containing common contaminants) by the Andromeda search engine embedded in MaxQuant
(Cox and Mann, 2008; Cox et al., 2011). MS1-based label free quantification (LFQ) was done using maxLFQ algorithm (Cox et al.,
2014). We require a minimum of two peptide ratios in order to consider a given protein as valid (protein and peptide ID
FDR=0.01). Perseus platform (Tyanova et al., 2016) was used to perform data filtering and statistical testing. In step 1, contaminant
hits, reverse identification hits, and proteins ‘‘only identified by site’’ were removed from the dataset. In step 2, LFQ intensities were
log2 transformed. This was followed by categorical annotation to create two samples groups based on their treatment. Step 3
involved removal of missing quantitative data points to minimize the number of missing values in the dataset and this was followed
by missing value data imputation using a normal distribution simulating the distribution of low abundant proteins in the dataset.
Lastly, Student’s t-test was utilized to define differentially expressed proteins employing a two-fold change as a cut-off at a 5% FDR.
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Flow Cytometry and Confocal Microscopy
Flow cytometric staining was performed as previously described (Chang et al., 2015). All fluorochrome-conjugated monoclonal an-
tibodieswere from (eBioscience), except for anti-CD301 (BioRad). Both NOS2 andRELMaprotein levels were quantified after fixation
and permeabilisation using the transcription buffer staining set (eBioscience) and monoclonal antibodies against NOS2 (Santa Cruz)
and RELMa (Peprotech). eIF5A and eIF5AH levels were quantified using anti-eIF5A (BD Bioscience) anti-hypusine (Merck-Millipore)
after fixation and permeabilisation using the CytoFix/CytoPerm kit (BD Bioscience). Cells were stained with Live/Dead viability dye
(Thermo) prior to antibody staining. Cells were collected on LSR II and Fortessa flow cytometers (BDBiosciences) and analysed using
FlowJo (TreeStar) software. Cells were sorted using a FACS Aria II. Cells were imaged using a Zeiss spinning disk confocal micro-
scope with an Evolve (EMCCD) camera. Cells were kept in a humidified incubation chamber at 37C with 5% CO2 during image
collection. Images were deconvolved using Huygens essential software (Scientific Volume Imaging) and analysed using Imaris soft-
ware (Bitplane). To verifymitochondrial localization of theMTSmCherry constructs, cell were stainedwith 100nMMitotrackerDeep
Red FM (Thermo) for 30 minutes at 37C, washed twice and analyzed using an ImageStream X Mark II Imaging Flow Cytometer
(Merck Millipore).
RT-PCR
RNA was isolated using the RNeasy kit (Qiagen) and single-strand cDNA was synthesized using the High Capacity cDNA Reverse
Transcription Kit (Applied Biosystems). All RT-PCR was performed with Taqman primers using an Applied Biosystems 7000
sequence detection system. The expression levels of mRNA were normalized to the expression of a housekeeping gene (b-actin).
Polysome Profile Analysis
Lysates were obtained by glass beads disruption as previously described (Jaiswal et al., 2011) in lysis buffer consisting of 20 mM
HEPES-KOH pH 7.4, 100 mM KAc, 2 mM MgAc2, 2 mM DTT, 1mM PMSF, 50 mg/ml cycloheximide and protease inhibitor mix:
1.25mg/ml leupeptin, 0.75 mg/ml antipain, 0.25 mg/ml chymostatin, 0.25 mg/ml elastinal, 5 mg/ml pepstatin A. Ten absorption units
(260 nm) of lysate were loaded onto linear 15%-to-55% sucrose gradients. After centrifugation at 200,000 x g for 2.5h at 4C, gra-
dients were separated from top to bottom into 20 fractions, from which RNA was harvested for RT-PCR.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analysis was performed using prism 6 software (Graph pad) and results are represented as mean ± SEM, unless otherwise
indicated. Comparisons for two groups were calculated using unpaired two-tailed Student’s t tests, comparisons of more than two
groups were calculated using one-way ANOVA with Bonferroni’s multiple comparison tests. We observed normal distribution and no
difference in variance between groups in individual comparisons. Statistical significance: * p<0.05; ** p < 0.005; *** p < 0.0005; **** p <
0.0001. Further details on statistical analysis are listed in the figure legends.
DATA AND SOFTWARE AVAILABILITY
All mass spectrometry raw data are deposited to the ProteomeXchange Consortium via PRIDE repository and are accessible with the
dataset identifier PXD013443.
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